Assess whether pediatric studies are necessary or waivable (dc264b)

Situation

Regulatory-affairs lead owns pediatric studies are necessary inside a safety team sitting on a new disproportionate signal with scientific-advice briefing book as the only packet. An AdCom briefing document that overstates subgroup findings is what changed the clock for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Pediatric studies are necessary / Waivable using scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Regulatory-affairs lead can defend Pediatric studies are necessary from scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings in a Pharma & Life Sciences challenge.
• Regulatory-affairs lead cannot defend Pediatric studies are necessary from scientific-advice briefing book; Waivable is what the extract actually supports after an AdCom briefing document that overstates subgroup findings.
• An AdCom briefing document that overstates subgroup findings never reached the population in scientific-advice briefing book — reopen intake, do not close pediatric studies are necessary.
• Two facts in scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings conflict for regulatory-affairs lead; hold this CMC and Development Pathways file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against an AdCom briefing document that overstates subgroup findings and write the one fact that would move pediatric studies are necessary for regulatory-affairs lead.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.